Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent Influenza Vaccine (Split Virion, Inactivated) Immunogenicity and Safety in Subjects Aged ≥3 Years
CTR20240998Phase 3Completed
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of quadrivalent inactivated split virion influenza vaccine in influenza, sponsored by Liaoning Chengda Biotechnology Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
quadrivalent inactivated split virion influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20240998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240998.